Stephane Altaba

CEO at Oncovita

Presenter

Oncovita is a cutting-edge biotech company and spin-off from Institut Pasteur, focused on developing life-saving immunovirotherapy treatments for cancer. Cancer remains the second leading cause of death worldwide. Despite advances in targeted therapies and immune checkpoint inhibitors (ICIs), response rates remain low (15-60%) and adverse events high (20-40%). At Oncovita, we're developing MVdeltaC, a novel recombinant measles vaccine virus that has shown strong immunogenic and oncolytic activity in preclinical stage and is set to enter the clinic in 2026. Starting with Mesothelioma and Triple-Negative Breast Cancer, we aim to leverage our measles vaccine-based platform to target all solid tumors.